New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.

An expanded collaboration between the two organizations will focus on prostate cancer and metastatic liver tumors, in addition to neurodegenerative disease.

Torres joins the medtech lobby from the FDA’s Center for Devices and Radiological Health, where she was associate director ...

The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.

Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation ...

Surgeons interested in robotic technology but wanting a simpler system than existing platforms are the target market for the ...

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study ...

Zimmer Biomet expects the shift of its U.S. salesforce to a more specialized, direct approach will help it better compete in ...

Hospital demand for IV solutions in the U.S. is lower than before Hurricane Helene, the company said.

Orthopedics was the most active area over the second half of 2025, with the FDA issuing 13 breakthrough designations to ...

Neurent Medical has raised 62.5 million euros ($74 million) to commercialize a device that treats a common nasal condition, the company said Wednesday. The Series C financing will equip Neurent to ...